The RUNX1 Research Program funds independent grants as well as grant programs in partnership with two prominent non-profit organizations fighting cancer: the Leukemia & Lymphoma Society (LLS) and Alex's Lemonade Stand Foundation (ALSF).
RRP currently has three grant-funding mechanisms: independent grants funded solely by RRP, and two separate co-funding partnership grants with LLS and ALSF.
The RUNX1 Research Program has partnered with the Leukemia and Lymphoma Society (LLS) to provide grants of $200,000 per year for three years for translational leukemia research related to the germline RUNX1 disorder.
The RUNX1 Research Program has partnered with Alex’s Lemonade Stand for Childhood Cancer to fund new and innovative research into therapeutics that would prevent the transition from the disorder to leukemia.
RRP Independent Grants
These grants have been awarded to investigators who are either developing fundamental reagents/resources for the field or are early in their career and have committed to focusing their attention on RUNX1-FPD.
Now Accepting Applications
RRP and Alex’s Lemonade Stand Foundation are pleased to announce that we are now accepting applications for the 2019 RUNX1 Early Career Investigator Grant Program.
The RUNX1 Research Program is proud to support innovative cancer research. Learn more about our grant awardees and their work.
Marc Raaijmakers, MD, PhD
Professor of Hematology, Erasmus MC Cancer Institute in Rotterdam, the Netherlands
Dr. Raaijmakers is a 2019 RRP/ALSF grantee. His research proposal aims to uncover whether RUNX1-FPD patients may be at heightened risk of blood cancer because of an unhealthy blood stem cell niche, which is the bone marrow.
Zuzana Tothova, MD, PhD
Investigator, Dana-Farber Cancer Institute
The RUNX1 gene encodes a protein that falls into a specific category of proteins called transcription factors. Transcription factors are proteins that can control the output of protein production from other genes.
Bringing it All Together: Conferences
In October we hosted our our 3rd annual Scientific Meeting at the Aspen Meadows Resort in Colorado. Scientists and clinicians from around the world came together at this mountain retreat to discuss the latest research on RUNX1-FPD.
Breaking New Ground
The NIH has just initiated the first-ever longitudinal natural history study of RUNX1-FPD patients, with the aim of better understanding the clinical features of the disease, how these may relate to the different germline mutations and why some patients progress to blood cancer and others do not. This is a groundbreaking study and essential in our effort to find a cure.